Infliximab vs adalimumab
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
- Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes onlyRR 0.09 [0.01, 1.54]1 study · 73 participantsVery low